Free shipping on all orders over $ 500

Gefitinib

Cat. No. M1749
Gefitinib Structure
Synonym:

ZD-1839, Iressa

Size Price Availability Quantity
300mg USD 90 In stock
500mg USD 140 In stock
1g USD 190 In stock
Bulk Inquiry?

Quality Control
Biological Activity

Gefitinib (ZD-1839, Iressa) is a novel potent EGFR tyrosine kinase inhibitor with an IC50 of 0.40nM.Gefitinib (ZD-1839,Iressa) selectively inhibited EGF-stimulated growth of HUVECs (IC50 = 0.03 - 0.1 µM) compared with FGF- or VEGF-stimulated growth (IC50 = 1 - 3 µM for both).Gefitinib is a competitive inhibitor with respect to ATP (Ki = 2.1 nM) when the peptide substrate concentration was fixed at 2 mM (6-fold higher than the Km) and the ATP concentration was varied.  Gefitinib showed noncompetitive kinetics (Ki = 15.0 nM) when the ATP concentration was 50 µM (6-fold higher than the Km) and the peptide concentration was varied.

Protocol
Cell Experiment
Cell lines MDA-361, SKBR-3, MDA-453 and BT-474 cells
Preparation method Monolayer Growth and Anchorage-independent Growth Assays. For monolayer growth, cells were seeded at a density of 3–4 104 cells in 12-well plates. Twenty-four h later, ZD1839 was added to the cells. Fresh medium ZD1839 was replaced on day 3. On day 5, cells were harvested by trypsinization and counted with a Zeiss Coulter Counter (Beckman Coulter, Miami, FL). Colony-forming assays in soft agarose were performed as described previously (30). Tumor cell colonies measuring 50 m were counted after 7 days using an Omnicon 3800 colony counter and Tumor Colony Analysis V2.IIA software (Imaging Products International, Inc.).
Concentrations 0.1–10 µ M
Incubation time 4 days
Animal Experiment
Animal models BT-474 cells Xenograft in Athymic Mice
Formulation 0.05% Tween 80
Dosages 200 mg/kg/day for 28 days
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 446.90
Formula C22H24ClFN4O3
CAS Number 184475-35-2
Purity 99.45%
Solubility DMSO
Storage at -20°C
Customer Product Validations & Biological Datas
Source Clin Cancer Res (2017). Figure 2. Gefitinib (Abmole Bioscience)
Method apoptosis quantified
Cell Lines HCC4006 and H1975 cells
Concentrations 1μM
Incubation Time 72 h
Results We found directly inducing EMT by exogenous TWIST activation (Fig. 2) or chronic TGF- β treatment (Sup. Fig. 2) led to depressed levels of BIM resulting in suppression of EGFRi-induced apoptosis and resistance to EGFRi (WZ4002 and gefitinib).
Rating
References

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Lankheet NA et al. Biomed Chromatogr. 2012 Sep 17. PMID: 22987603.

A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Lee SJ et al. Invest New Drugs. 2012 Sep 18. PMID: 22987020.

Gefitinib-Induced Paronychia: Response to Autologous Platelet-Rich Plasma.
Kwon SH et al. Arch Dermatol. 2012 Sep 17;1-4. PMID: 22986691.

Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L et al. Curr Top Med Chem. 2012 Sep 11. PMID: 22978339.

Related EGFR/HER2 Products
Anlotinib

Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1,which can be used to treat non-small cell lung cancer.

Cetuximab

Cetuximab, a novel molecular-targeted agent,is an inhibitor of EGFR monoclonal humanized antibody interacting with the extracellular binding site of EGFR to block ligand stimulation. MW : 145.781 KD.

EAI045

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

Gefitinib HCl

Gefitinib Hcl(ZD-1839 Hcl) is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.

Erlotinib

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Gefitinib, ZD-1839, Iressa supplier, EGFR/HER2, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.